Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Tainted Heparin

May 12, 2008 | A version of this story appeared in Volume 86, Issue 19

I know it is easy to jump on the bandwagon and point a finger at outside suppliers when the issue of a contaminated drug arises (C&EN, March 31, page 8). However, I was amazed that none of the reports mentioned that, ultimately, the companies that put their names on the final product label, Baxter Healthcare and B. Braun Medical in the case of contaminated heparin, should take responsibility for ensuring that their supplier meets predetermined specifications before accepting any lots of active pharmaceutical ingredients (API). If they had accepted the material and proceeded with drug product production, they must have agreed that the API was of acceptable quality.

A discussion on what acceptance criteria were set in the specifications and how the contaminant escaped the companies’ quality-control/quality-assurance system may help readers understand the real issue and prevent other companies from repeating such mistakes.

Jessica Tan
Thousand Oaks, Calif.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.